The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis.
Idevaldo Floriano, Antônio Silvinato, Wanderley Marques Bernardo
Revista da Associacao Medica Brasileira (1992) May 15, 2023 DOI: 10.1590/1806-9282.2023d694 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review protocol Randomized Peer reviewed |
|---|---|
| Interventions | Esketamine standard care (antidepressants) placebo |
| Duration | Minimum 25 days follow-up |
| Topics | Depression Ketamine Esketamine |
| Keywords | Humans Suicidal ideation |
| Key findings | The protocol outlines a planned systematic review to assess whether esketamine plus standard care improves depression in patients with major depression and suicidal ideation compared with placebo plus standard care, drawing on randomized controlled trials and observational studies with at least 25 days of follow-up. No findings are reported. |
Abstract
Eligibility criteria were as follows:1. Patients with major depression and suicidal ideation.2. Esketamine treatment plus standard care (antidepressants) compared to placebo plus standard care.3. Outcomes -improvement in the state of depression, evaluated in appropriate scores.4. Included randomized controlled trials (RCTs) and observational studies. 5.No restrictions on publication date and language.6. Full text available for access.7. Follow-up time: minimum 25 days.The search for evidence will be carried out in the Medline/ PubMed and Central Cochrane virtual scientific information base, using the following search strategy: (Depressive Disorder OR Depressive Disorder, Major OR Depressive Disorder, Treatment-Resistant) AND Esketamine AND Random*.The search in these databases was carried out until the month of
Comparable studies
Other systematic reviews and meta-analyses on esketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Adults with unipolar or bipolar major depression | 2020 | Systematic review and meta-analysis | n = 1,877 |
| The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. Participants in randomized controlled trials of ketamine for suicidal ideation | 2020 | Systematic review and meta-analysis | n = 197 |
| Efficacy of Esketamine Augmentation in Major Depressive Disorder Patients with major depressive disorder who are treatment-resistant or acutely suicidal | 2020 | Systematic review and meta-analysis | n = 774 |
| Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. Patients with treatment-resistant major depressive disorder | 2025 | Systematic review and meta-analysis | |
| EFFICACY AND SAFETY OF RACEMIC KETAMINE AND ESKETAMINE FOR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS Adults with unipolar or bipolar major depression | 2022 | Systematic review and meta-analysis | n = 2,903 |